Navigation Links
Toward more cost-effective production of biofuels from plant lignocellulosic biomass
Date:11/16/2011

In 1925, Henry Ford observed that fuel is present in all vegetative matter that can be fermented and predicted that Americans would some day grow their own fuel. Last year, global biofuel production reached 28 billion US gallons, and biofuel accounted for 2.7% of the world's transportation fuel. Bioethanol, a popular type of biofuel, is largely derived from sugary food crops such as corn and sugarcane. However, technologies are being developed to generate bioethanol from non-food sources, such as the lignocellulosics present in switchgrass and trees. The sugars locked in the polymers of cell walls, i.e., cellulose, hemicellulose and lignin, can be extracted and fermented by yeast into bioethanol.

A major obstacle to this strategy is that most wall polysaccharides are O-acetylated (i.e., chemically bonded to acetate groups), and the acetate released from these molecules during processing inhibits the activity of the microbes that ferment sugars into alcohol. Based on techno-economical models, a 20% reduction in biomass acetylation is predicted to translate into a 10% reduction in bioethanol price. Thus, a major goal in the field of plant biofuel research is to diminish the O-acetate content in the cell walls of plants, possibly by blocking the enzymes that acetylate the cell wall polymers. However, little is known about the acetylation enzymes in plants.

A team of researchers at the Energy Biosciences Institute, University of California, Berkeley, set out to identify the enzymes that acetylate the polysaccharides that are present in lignocellulosic feedstocks. Their initial work focused on xyloglucan, a type of hemicellose that is abundant in plant cell walls. Using a mass spectrometric technique, the scientists isolated a mutant from amongst a mutagenized population of the model plant Arabidopsis (a member of the mustard and cabbage family) that exhibited a 20-45% reduction in xyloglucan O-acetylation. The researchers mapped the mutation to a physical location in the Arabidopsis genome, and named the gene locus ALTERED HEMICELLULOSE XYLOGLUCAN 4 (AXY4). Blocking the expression of AXY4 in Arabidopsis eliminates xyloglucan O-acetylation.

A natural variety of Arabidopsis growing in northern Scotland also has low levels of xyloglucan O-acetylation. Intriguingly, this variety was found to have a natural mutation in the same gene - AXY4. This finding demonstrates that lack of xyloglucan O-acetylation does not represent a selective disadvantage for the plant, and supports the feasibility of genetically blocking the expression of the protein that controls O-acetylation in plants destined for biofuel production.

"The identification of the first gene to encode a polysaccharide O-acetyltransferase opens the door for identifying similar genes in bioenergy crop feedstocks, such as miscanthus or other energy-grasses. These genes can be used as genetic markers to facilitate breeding programs that aim to generate biofuel feedstocks with reduced lignocellulosic acetate content," says Markus Pauly, a plant biologist at Berkeley's Energy Biosciences Institute.


'/>"/>

Contact: Kathleen L. Farquharson
kfarquharson@aspb.org
206-324-2126
American Society of Plant Biologists
Source:Eurekalert  

Related biology news :

1. Leicester leads the way towards a sustainable lake in Africa
2. Advance toward a breath test to diagnose multiple sclerosis
3. Progress towards developing plants that accommodate climate change
4. Wildlife Conservation Society study uncovers a predictable sequence toward coral reef collapse
5. Award-winning research points toward Alzheimer’s vaccine
6. Another step toward resisting breast cancer
7. Toward new medications for chronic brain diseases
8. Toward a more efficient use of solar energy
9. Toward a green grid for delivering solar and wind-based electricity
10. Progress toward the clinical application of autologous induced pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia
11. An advance toward blood transfusions that require no typing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Toward more cost-effective production of biofuels from plant lignocellulosic biomass
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: